Drug Trial Radar · NCT07481955
Chlorhexidine and/or Metronidazole Plus FB301 Pre-treatment Trial
Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Mar 23, 2026
Primary completion
Mar 3, 2027
Study completion Apr 21, 2027
Sponsor
- Lead sponsor
- Freya Biosciences ApSIndustry
- Sponsor type
- Industry
- Collaborators
- CRS Clinical Research Services Berlin GmbH; CRS Clinical Research Services Mannheim GmbH
- First posted
- Mar 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to evaluate how treatment with FB301 affects the balance of vaginal bacteria in women (aged 18-45) with bacterial vaginosis after pre-treatment with either a vaginal antiseptic wash (chlorhexidine), an oral antibiotic (metronidazole), or both. The main question it aims to answer is: Does treatment with FB301, with or without pre-treatment using a vaginal antiseptic (chlorhexidine) or an oral antibiotic (metronidazole), change the balance of vaginal bacteria, measured by the proportion of two key bacteria (Lactobacillus crispatus and Lactobacillus jensenii), between the start of treatment and follow-up visits over the next 10 weeks? Researchers will compare participants randomly assigned to 4 different groups: * Group 1 will receive FB301for 15 days with the antibiotic (metronidazole) for the first seven days. In the next menstrual cycle, they will receive just FB301 for an additional 15-days. * Group 2 will receive FB301for 15 days. On the first day only, they will first undergo a vaginal cleanse with chlorhexidine (antiseptic solution). In the next menstrual cycle, they will receive just FB301 for an additional 15-days. * Group 3 will receive FB301for 15 days with the antibiotic (metronidazole) for the first seven days. On the first day only, they will first undergo a vaginal cleanse with chlorhexidine (antiseptic solution). In the next menstrual cycle, they will receive FB301 for an additional 15-days following a vaginal cleanse with chlorhexidine (antiseptic solution) on the first day only. * Group 4 will receive just FB301for 15 days. In the next menstrual cycle, they will receive just FB301 for an additional 15-days. Participants will: * Attend the study centre for up to 6 visits * Provide vaginal swab samples at up to 6 visits * Provide vaginal secretion samples using a menstrual disc at up to 4 visits * Have blood samples taken at up to 6 visits * Receive the study treatments for the randomly assigned group over two consecutive menstrual cycles.
Conditions
- Bacterial Vaginosis (BV)
Interventions
FB 301Drug
FB 301 capsule
Chlorhexidine 0.5%Drug
Vaginal cleanse with 0.5% Chlorhexidine solution
metronidazole 500 mgDrug
Metronidazole 500 mg tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- The change in vaginal microbiome in terms of relative abundance of combined Lactobacillus crispatus and jensenii speciesTime frame: Baseline to visit 3 (week 3)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
CRS Clinical Research Services Mannheim
Mannheim, Germany · Recruiting
CRS Clinical Research Services Berlin GmbH
Berlin, State of Berlin, Germany · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.